Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study

Charitha Gowda,1 Stephen Lott,3 Matthew Grigorian,6 Dana M. Carbonari,1 M. Elle Saine,4 Stacey Trooskin,5,6 Jason A. Roy,1 Jay R. Kostman,5, Paul Urick,3 and Vincent Lo Re III2,4,6

INTRODUCTION

All-oral, direct-acting antiviral (DAA) regimens for the treatment of chronic hepatitis C virus (HCV) infection have been available since 2014 [1]. These regimens result in high (≥294%) rates of cure and have been associated with few adverse effects [2]. Viral eradication can help to eliminate HCV transmission [3, 4], reduce the risk of liver complications [5], decrease extrahepatic manifestations of disease [6], and prolong survival [7]. As a result, HCV management guidelines from the American Association for the Study of Liver Diseases/Infectious Diseases Society of America have recommended DAA treatment for all chronic HCV-infected patients [8]. The ability to cure chronic HCV in nearly all infected people makes the prospect of eliminating HCV in the United States possible [9].

Despite the acknowledged benefits of HCV therapy [10], the high costs of DAAs have led public and private insurers in the United States to restrict access to these medications [11]. Insurers established varying criteria for reimbursement of DAAs, such as evidence of advanced liver fibrosis, consultation with a specialist, and/or abstinence from alcohol or illicit drug use [12, 13]. Restrictions for reimbursement of DAAs have been shown to be common across state Medicaid programs [14–16]. Analyses conducted shortly after the release of DAAs into the market showed that the downstream effect of these restrictions, absolute denial by insurers, was common overall, but more frequent among patients covered by Medicaid than Medicare or commercial insurance [17, 18]. However, these studies were not nationally representative and evaluated access to DAAs during their initial availability only.

Over the last 2 years, advocacy efforts by stakeholders, class action lawsuits, threats of legal action, and greater price competition due to the availability of new DAAs have led to relaxations...
of restrictions in DAA reimbursement within a variety of settings [19–21]. Consequently, it is important to examine how access to DAAAs has changed since their initial release.

We determined the incidence of absolute denial of DAA therapy by type of insurance in a national sample of chronic HCV-infected patients prescribed DAA therapy between January 2016 and April 2017. Given the relaxation of restrictions in DAA reimbursements across a number of settings, we hypothesized that the overall incidence of absolute denial was lower than in initial reports [17, 18] and has declined over time.

**METHODS**

**Study Design and Data Source**

We conducted a prospective cohort study using data from Diplomat Pharmacy, Inc., which provides specialty pharmaceuticals, including DAAAs, to patients across the United States. DAAAs are often dispensed by specialty pharmacies because of their high costs and requirements for special handling and delivery [22]. For each DAA prescription, Diplomat contacts the prescribing clinician, obtains information required by the insurer to determine medical need for DAA treatment, and submits this to the insurer for review. Final decision on DAA fill (approval or denial) is provided to the pharmacy from the insurer, typically within 30 days. Diplomat uses an electronic record system to record data on demographics, health insurance, and prescribed medications. HCV-related clinical data, such as HCV genotype, stage of hepatic fibrosis, alcohol consumption, and HIV status, are not electronically available for all patients with a submitted DAA prescription. The study was approved by the University of Pennsylvania Institutional Review Board.

**Study Patients**

Chronic HCV-infected patients with health insurance were included if they had a DAA prescription submitted to Diplomat between January 1, 2016, and April 30, 2017. If a patient had multiple DAA treatment courses prescribed during the period of interest, only the first regimen was included. Follow-up began on the date that the DAA prescription was received by Diplomat. Observation continued until the pharmacy ascertained the final outcome for the prescription (ie, absolute denial or DAA prescription fill).

**Main Study Outcome**

The primary outcome was absolute denial of DAA prescription, defined as lack of approval of DAA fill by the insurer. The status of all prescriptions with insurers was ascertained through August 31, 2017. Insurers’ requests for alternative DAA regimens due to formulary restrictions were not recorded as absolute denials.

**Data Collection**

Demographic and pharmacy data collected from Diplomat’s electronic records at the time the DAA prescription was received by the pharmacy included age, sex, state of residence, type of insurance, and DAA regimen prescribed. Type of insurance was determined based on the insurance plan to which the DAA prescription was submitted and was classified as Medicaid (joint federal- and state-funded programs for medical care and drug benefits for low-income and special needs individuals [23]), Medicare (federal health insurance program available to Americans aged ≥65 years and to some <65 years with certain disabilities or chronic health conditions [24]), or commercial insurance (health benefits that are employer sponsored, privately purchased, or obtained via health exchange through the Affordable Care Act [25]). For patients covered by Medicaid, we also determined enrollment in a fee-for-service or managed care plan.

**Statistical Analysis**

Differences in patients’ characteristics by type of insurance (Medicaid, Medicare, or commercial insurance) were assessed using chi-square tests for categorical data and Kruskal-Wallis tests for continuous data.

We calculated the incidence and 95% confidence intervals (CIs) of absolute denial of DAA prescription, overall and by type of insurance, for the total 16-month study period and for each quarter. We included April 2017 within the final quarter (January–April 2017) for these analyses. We determined tests for trend to assess the significance of changes in the incidence of absolute DAA denial over time. In addition, we calculated the proportion of absolute denials within each state, overall and by insurance type. Data were analyzed using Stata 12.1 (Stata Corporation, College Station, TX).

**RESULTS**

Between January 1, 2016, and April 30, 2017, Diplomat received DAA prescriptions for 9025 patients from 45 US states (4702 covered by Medicaid; 1821 by Medicare; 2502 by commercial insurance). Medicaid patients were younger than those with Medicare or commercial insurance (Table 1).

Among these 9025 patients, 3200 (35.5%; 95% CI, 34.5%–36.5%) received an absolute denial of their treatment (Figure 1; Supplementary Table 1). Throughout the observation period, the incidence of absolute denial was more common among patients covered by commercial insurance (52.4%) than by Medicaid (34.5%, P < .001) or Medicare (14.7%, P < .001). Among Medicaid beneficiaries, the overall incidence of absolute denial was higher among those with fee-for-service (47.5%) than managed care plans (32.6%, P < .001).

The incidence of absolute denial increased across each quarter of the 16-month study period when examined overall (27.7% in the first quarter to 43.8% in the last quarter; test for trend, P < .001) and for each type of insurance (test for trend, P < .001 for each type) (Figure 1). Among Medicaid beneficiaries, patients enrolled in managed care plans experienced an increase in the incidence of absolute denial over time (test for trend, P < .001); however, no change over time was observed for
those enrolled in fee-for-service plans (test for trend, $P = .34$) (Supplementary Table 1).

Among the 45 states from which a DAA prescription was submitted during the observation period, 8 states contributed 90% of prescriptions: Pennsylvania (2839 [31.5%]), California (2133 [23.6%]), Michigan (1292 [14.3%]), Massachusetts (557 [6.2%]), New Jersey (553 [6.1%]), Delaware (316 [3.5%]), Oregon (231 [2.6%]), and Maryland (167 [1.9%]) (Table 2).

The overall incidence of absolute DAA denial varied by type of insurance within and across states (Figure 2; Table 2). Among prescriptions submitted from these 8 states, the overall incidence of absolute denial was higher in Maryland (86/167 [51.5%]), Delaware (155/316 [49.1%]), New Jersey (261/553 [47.2%]), and Pennsylvania (1297/2839 [45.7%]) than those in the other 4 states.

**DISCUSSION**

For DAA prescriptions submitted to a national specialty pharmacy between January 2016 and April 2017, 35.5% were absolutely denied by the insurance carrier. The incidence of absolute

---

**Table 1. Characteristics of Chronic Hepatitis C Virus–Infected Patients for Whom a Direct-Acting Antiviral Prescription Was Received by the Specialty Pharmacy Between January 2016 and April 2017, Overall and by Type of Insurance**

| Characteristic | Overall | Medicaid | Medicare | Commercial Insurance | $P$ Value |
|---------------|---------|----------|----------|-----------------------|-----------|
| No. (%) with DAA prescription submitted to pharmacy | 9025 | 4702 (52.1) | 1821 (20.2) | 2502 (27.7) |          |
| Median age (IQR), y | 57 (49–62) | 55 (45–60) | 64 (58–68) | 58 (49–62) | <.001    |
| Female sex, No. (%) | 3463 (38.4) | 1834 (39.0) | 714 (39.2) | 915 (36.6) | .200     |
| DAA regimen prescribed, No. (%) |          |          |          |          | <.001    |
| Sofosbuvir/velpatasvir +/- ribavirin | 1726 (19.1) | 1026 (21.8) | 213 (11.7) | 487 (19.5) |          |
| Sofosbuvir/ledipasvir +/- ribavirin | 4862 (51.7) | 1957 (41.6) | 1213 (66.6) | 1492 (59.6) |          |
| Sofosbuvir + ribavirin | 392 (4.3) | 212 (4.5) | 79 (4.3) | 101 (4.0) |          |
| Sofosbuvir + simeprevir +/- ribavirin | 9 (0.1) | 4 (0.1) | 3 (0.2) | 2 (0.1) |          |
| Paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin | 402 (4.5) | 217 (4.6) | 30 (1.7) | 155 (6.2) |          |
| Paritaprevir/ritonavir/ombitasvir +/- ribavirin | 9 (0.1) | 6 (0.1) | 2 (0.1) | 1 (0.04) |          |
| Elbasvir/grazoprevir +/- ribavirin | 1316 (14.6) | 994 (21.1) | 177 (9.7) | 145 (5.8) |          |
| Daclatasvir + sofosbuvir +/- ribavirin | 495 (5.5) | 279 (5.9) | 100 (5.5) | 116 (4.6) |          |
| Pegylated interferon alfa + sofosbuvir + ribavirin | 14 (0.2) | 7 (0.2) | 4 (0.2) | 3 (0.1) |          |

Abbreviations: DAA, direct-acting antiretroviral; IQR, interquartile range.

**Figure 1. Incidence of absolute denial of direct-acting antiviral regimen documented by the specialty pharmacy over the specified time period according to type of insurance, overall and by quarter of calendar year. Abbreviation: CI, confidence interval.**
Table 2. Incidence of Absolute Denial of Direct-Acting Antiviral Regimen Documented by the Specialty Pharmacy Between January 2016 and April 2017, According to Patient’s Insurance and State of Residence

| State | Overall | Medicaid | Medicare | Commercial Insurance |
|-------|---------|----------|----------|----------------------|
|       | No. Submitted (% of Total) | No. Denied (% of Submitted) | No. Submitted | No. Denied (% of Submitted) | No. Submitted | No. Denied (% of Submitted) | No. Submitted | No. Denied (% of Submitted) |
| Overall | 9025 (100.0) | 3200 (35.5) | 4702 (30.4) | 1821 (19.9) | 268 (14.7) | 2502 (100.0) | 1312 (52.4) |
| AL | 17 (0.2) | 3 (17.7) | 0 | 0 | 0 | 13 (17.7) | 4 | 2 (60.0) |
| AK | 2 (0.02) | 1 (50.0) | 0 | 0 | 0 | 0 | 2 | 1 (50.0) |
| AZ | 44 (0.5) | 22 (50.0) | 14 | 13 (92.9) | 9 | 0 | 21 | 9 (42.9) |
| AR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CA | 2133 (23.6) | 360 (16.9) | 1780 | 247 (13.9) | 183 | 35 (19.1) | 170 | 78 (45.9) |
| CO | 31 (0.3) | 22 (71.0) | 1 | 1 (100.0) | 6 | 2 (33.3) | 24 | 19 (79.2) |
| CT | 20 (0.2) | 9 (45.0) | 3 | 1 (33.3) | 6 | 0 | 11 | 8 (72.7) |
| DE | 316 (3.5) | 155 (49.1) | 110 | 74 (67.3) | 76 | 8 | 130 | 73 (56.2) |
| FL | 45 (0.5) | 23 (51.1) | 8 | 6 (75.0) | 17 | 4 | 20 | 13 (65.0) |
| GA | 23 (0.3) | 10 (43.5) | 5 | 4 (80.0) | 8 | 0 | 10 | 6 (60.0) |
| HI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ID | 17 (0.2) | 3 (17.7) | 2 | 1 (50.0) | 8 | 0 | 7 | 2 (28.6) |
| IL | 107 (1.2) | 50 (46.7) | 17 | 16 (94.1) | 33 | 4 (12.1) | 57 | 30 (52.6) |
| IA | 1 (0.01) | 1 (100.0) | 0 | 0 | 0 | 0 | 1 | 1 (100.0) |
| IN | 16 (0.2) | 7 (43.8) | 4 | 3 (75.0) | 3 | 0 | 9 | 4 (44.4) |
| KS | 4 (0.04) | 0 (0.0) | 0 | 0 | 0 | 1 | 3 | 0 (0.0) |
| KY | 25 (0.3) | 5 (20.0) | 3 | 3 (100.0) | 15 | 0 | 7 | 2 (28.6) |
| LA | 3 (0.03) | 1 (33.3) | 0 | 0 | 0 | 0 | 3 | 1 (33.3) |
| ME | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MD | 167 (1.9) | 86 (51.5) | 46 | 32 (69.6) | 52 | 7 | 69 | 47 (68.1) |
| MA | 557 (6.2) | 110 (19.8) | 466 | 78 (16.7) | 16 | 3 | 75 | 29 (38.7) |
| MI | 1292 (14.3) | 477 (36.9) | 462 | 232 (50.2) | 379 | 41 | 451 | 204 (45.2) |
| MN | 9 (0.1) | 6 (66.7) | 3 | 3 (100.0) | 1 | 1 | 5 | 2 (40.0) |
| MS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MO | 14 (0.2) | 0 (0.0) | 1 | 0 (0.0) | 1 | 0 (0.0) | 12 | 0 (0.0) |
| MT | 21 (0.2) | 9 (42.9) | 0 | 0 | 0 | 1 | 20 | 8 (40.0) |
| NE | 1 (0.01) | 1 (100.0) | 0 | 0 | 0 | 0 | 1 | 1 (100.0) |
| NV | 75 (0.8) | 25 (33.3) | 2 | 2 (100.0) | 24 | 3 | 49 | 20 (40.8) |
| NH | 9 (0.1) | 4 (44.4) | 3 | 3 (100.0) | 1 | 0 | 5 | 1 (20.0) |
| NJ | 553 (6.1) | 261 (47.2) | 199 | 129 (64.8) | 148 | 14 | 206 | 118 (57.3) |
| NM | 2 (0.02) | 0 (0.0) | 0 | 0 | 0 | 2 | 0 | 0 |
| NY | 6 (0.07) | 5 (83.3) | 0 | 0 | 0 | 0 | 6 | 5 (83.3) |
| NC | 118 (1.3) | 44 (37.3) | 25 | 12 (48.0) | 58 | 8 | 35 | 24 (68.6) |
| ND | 4 (0.04) | 1 (25.0) | 0 | 0 | 0 | 0 | 4 | 1 (25.0) |
| OH | 26 (0.3) | 8 (30.8) | 4 | 3 (75.0) | 11 | 1 | 11 | 4 (36.4) |
| OK | 4 (0.04) | 3 (75.0) | 1 | 0 (0.0) | 0 | 0 | 3 | 3 (100.0) |
| OR | 231 (2.6) | 46 (19.9) | 186 | 32 (17.2) | 13 | 1 | 32 | 13 (40.6) |
| PA | 2839 (31.5) | 1297 (45.7) | 1294 | 676 (52.2) | 662 | 124 | 883 | 497 (56.3) |
| RI | 4 (0.04) | 4 (100.0) | 3 | 3 (100.0) | 1 | 1 | 0 | 0 |
| SC | 23 (0.3) | 5 (21.7) | 1 | 1 (100.0) | 19 | 1 | 3 | 3 (100.0) |
| SD | 1 (0.01) | 1 (100.0) | 0 | 0 | 0 | 0 | 1 | 1 (100.0) |
| TN | 9 (0.1) | 2 (22.2) | 0 | 0 | 0 | 0 | 9 | 2 (22.2) |
| TX | 89 (1.0) | 47 (52.8) | 3 | 3 (100.0) | 28 | 6 | 58 | 38 (65.5) |
| UT | 10 (0.1) | 9 (90.0) | 4 | 4 (100.0) | 0 | 0 | 6 | 5 (83.3) |
| VT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| VA | 13 (0.1) | 6 (46.2) | 3 | 3 (100.0) | 3 | 0 (0.0) | 7 | 3 (42.9) |
| WA | 61 (0.7) | 27 (44.3) | 19 | 13 (68.4) | 3 | 0 (0.0) | 39 | 14 (35.9) |
| WV | 8 (0.09) | 6 (75.0) | 3 | 2 (66.7) | 1 | 1 | 4 | 3 (75.0) |
| WI | 70 (0.8) | 36 (51.4) | 27 | 20 (74.1) | 19 | 1 | 24 | 15 (62.5) |
| WY | 5 (0.06) | 2 (40.0) | 0 | 0 | 0 | 0 | 5 | 2 (40.0) |
denial was higher among commercially insured (52.4%) and Medicaid (34.5%) beneficiaries compared with Medicare beneficiaries (14.7%). Notably, the incidence of denial increased for all insurance types over subsequent quarters during the observation period. Finally, the incidence of absolute DAA denial varied by type of insurance within and across states.

Contrary to our hypothesis, the overall incidence of absolute denial in this study (35.5%) was substantially higher in magnitude than that observed in 2 prior analyses conducted shortly after the release of all-oral DAA regimens (absolute denial range, 8.2%–16.2%) [17, 18]. The reason for this higher-than-expected denial rate is unclear, but may be due to attempts to treat chronic HCV-infected patients who have less advanced liver fibrosis, have not met sobriety restrictions, or have not had consultation with a specialist.

In prior studies, denial of DAA therapy was reported to occur in as high as 46.3% of Medicaid beneficiaries [17, 18]. In contrast, the results of the present study indicate that the overall incidence of absolute denial of DAAs is now lower in magnitude for Medicaid beneficiaries (34.5%). The lower overall absolute denial rate of DAAs among Medicaid beneficiaries is likely a consequence of the statement by the Centers for Medicare and Medicaid Services that restriction of access to DAAs based on cost containment violates federal law [26], following reports highlighting restrictions on reimbursement of DAAs across state Medicaid programs [14, 15]. This notification prompted class action lawsuits and threats of legal action against some state Medicaid programs [27–29]. These efforts contributed to changes in the criteria for reimbursement of DAAs across a number of Medicaid programs [16]. There have been several notable trends in Medicaid HCV treatment criteria in recent years, including more transparency in treatment restrictions, decreased restrictions particularly for the degree of liver fibrosis, and more information on restrictions imposed by managed care organizations [19]. However, as Table 2 and Figure 2 demonstrate, there remains considerable heterogeneity in the incidence of absolute denial across state Medicaid programs, presumably due to the varying criteria for reimbursement across these programs [14–16].

Figure 2. Incidence of absolute denial of direct-acting antiviral regimen documented by the specialty pharmacy between January 2016 and April 2017 according to patient’s state of residence, overall (A) and by type of insurance (B: Medicaid; C: Medicare; D: commercial insurance).
We found that among Medicaid beneficiaries, the overall incidence of absolute denial was higher among those with fee-for-service than managed care plans. However, Medicaid patients enrolled in managed care plans experienced an increase in the incidence of absolute denial over time, while no change was observed for those enrolled in fee-for-service plans. The increase in denial for Medicaid patients in managed care plans is concerning since Medicaid programs, by law, must ensure that their managed care organizations offer either similar or less restrictive coverage than the fee-for-service plans in the same state [30]. Regulators should ensure that parity in access to DAA treatments between Medicaid fee-for-service and managed care programs is monitored and enforced.

Our study found a substantially higher incidence of absolute denial for patients covered by Medicare (14.7%) and commercial insurance (52.4%) than that reported in prior studies [17, 18]. Those reports showed that 2.5%–5.0% of Medicare beneficiaries and 5.9%–10.2% of commercially insured individuals had their DAA regimens absolutely denied. Little is known about restrictions to HCV treatment among Medicare and commercial insurance beneficiaries. It is possible that these plans were less restrictive shortly after the release of DAAs but became more restrictive in their reimbursement policy over time. Our data highlight the need for transparency in defining criteria for restriction by all insurers, including commercial insurance and Medicare Part D plans.

Also contrary to our hypothesis, we observed that the incidence of absolute denial increased over time, regardless of insurance type. The reasons for this increase remain unclear. The combination of cost and demand for DAA treatments has strained the budgets of many payers since these drugs became available [12]. As a result, insurers may be electing to prioritize certain patient populations, such as those who have advanced hepatic fibrosis/cirrhosis or who abstain from alcohol and injection drug use, when deciding whether to allocate DAA treatments [11–13]. Future studies should evaluate the reasons for the increasing denials across insurance plans as well as denial rates in specific patient groups.

The high incidence of absolute denial of DAA therapy has important implications. From a clinical standpoint, patients denied access to HCV therapy remain at risk for the development of hepatic fibrosis, cirrhosis, liver decompensation, and hepatocellular carcinoma. Denial of DAA treatment can also lead to ongoing HCV-associated inflammation, which might increase the risk of extrahepatic complications. Further, failure to treat and cure chronic HCV maintains a reservoir of HCV transmission. From a public health standpoint, the high incidence of absolute denial of DAA treatment represents a major barrier to the goal of HCV elimination. A recent report by the National Academies of Sciences, Engineering, and Medicine determined that at least 260,000 chronic HCV-infected patients must be treated yearly to achieve elimination of HCV in the United States by 2030 [9]. Given the clinical benefits of curing chronic HCV infection [10], cost-effectiveness of DAA treatment [31–33], and importance of antiviral therapy to HCV elimination efforts, the National Academies’ report recommended that public and private insurers should remove restrictions to DAAs that are not medically indicated and offer treatment to all chronic HCV-infected patients [9]. This recommendation is consistent with guidelines from the American Association for the Study of Liver Diseases/Infectious Diseases Society of America that recommend DAA treatment for all patients with chronic HCV infection [8]. The high incidence of denial of HCV therapy adversely impacts strategies for HCV elimination.

This study had several potential limitations. First, the specialty pharmacy did not electronically record certain data elements in a manner that could be obtained for the purpose of this study. The pharmacy did not record the date of the final disposition of the DAA prescription as a distinct data field, preventing us from calculating the median time to DAA fill or denial. Extractable HCV-related data were not available for all patients with a submitted DAA prescription. As a result, we were unable to identify factors that were independently associated with absolute DAA denial. Data on interim denials and appeals were also not electronically recorded. Second, insurers did not provide the specialty pharmacy with their reasons for denial, which were only submitted to the patients. We therefore were unable to confirm the precise reasons for the high incidence of absolute denial within and across insurance types. Finally, while our analysis was nationally representative, 8 states constituted the majority of the data, and data on 5 states were not available at all because the specialty pharmacy did not service those regions.

In conclusion, despite the availability of new DAA regimens and changes in restrictions to these therapies, absolute denials of DAA regimens by insurers have remained high and increased over time, regardless of type of insurance. These data provide evidence of a continued lack of access to HCV therapy across insurance types. To achieve the goal of HCV elimination [9], access to antiviral treatment must be improved.

Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments
Financial support. This work was supported by grant funding from the Penn Center for AIDS Research (CFAR), a National Institutes of Health–funded program (P30 AI 045008), and the National Institutes of Health (T32AG051090 to M.E.S.).

Potential conflicts of interest. S.L. and M.G. are employees of EnvoyHealth. S.T. has received investigator-initiated research grant support (to the Philadelphia Field Initiating Group for HIV Trials) from Gilead Sciences and has served on an advisory board for Gilead Sciences. J.R.K. has served on an advisory board for Gilead Sciences. All other authors report no relevant conflicts of interest. All authors have submitted the ICMJE
Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
1. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014; 312:631–40.
2. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 2017; 166:637–48.
3. Harris RJ, Martin NK, Rand E, et al. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat 2016; 23:631–43.
4. Martin NK, Thornton A, Hickman M, et al. Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights. Clin Infect Dis 2016; 62:1072–80.
5. Backus LJ, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology. 2017; [Epub ahead of print].
6. Mahale P, Engels EA, Li R, et al. The effect of sustained virological response on the risk of extrahaematological manifestations of hepatitis C virus infection. Gut 2018; 67:553–61.
7. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:258–93.
8. American Association for the Study of Liver Diseases/Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org/. Accessed 19 October 2017.
9. National Academies of Sciences, Engineering, and Medicine. 2017. A National Strategy for the Elimination of Hepatitis B and C: Phase One Report. Washington, DC: The National Academies Press. Available at: http://www.nationalacademies.org/hmd/Reports/2017/national-strategy-for-the-elimination-of-hepatitis-b-and-c.aspx. Accessed 17 October 2017.
10. Lok AS, Chung RT, Vargas HE, et al. Benefits of direct-acting antivirals for hepatitis C. Ann Intern Med 2017; 167:812–3.
11. Troncosin SB, Reynolds H, Kostman JR. Access to costly new hepatitis C drugs: medicine, money, and advocacy. Clin Infect Dis 2015; 61:1825–30.
12. Simon RE, Pearson SD, Hur C, Chung RT. Tackling the hepatitis C cost problem: a test case for tomorrow’s cures. Hepatology 2015; 62:1334–6.
13. Grebely J, Haire B, Taylor LE, et al; International Network for Hepatitis in Substance Users. Excluding people who use drugs or alcohol from access to hepatitis C treatments – is this fair, given the available data? J Hepatol 2015; 63:779–82.
14. Barua S, Greenwald R, Grebely J, et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163:215–23.
15. Canary LA, Klevens RM, Holmgren SD. Limited access to new hepatitis C virus treatment under state Medicaid programs. Ann Intern Med 2015; 163:226–8.
16. Osoka K, Connolly JJ, Lim JK. Medicaid reimbursement for oral direct-acting viral agents for the treatment of chronic hepatitis C. Am J Gastroenterol 2017; 112:828–32.
17. Lo Re V, Jrd, Gowda C, Urick PN, et al. Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol 2016; 14:1035–43.
18. Younossi ZM, Bacon BR, Dieterich DT, et al. Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO study. J Viral Hepat 2016; 23:447–54.
19. National Viral Hepatitis Roundtable and Center for Health Law & Policy Innovation, Harvard Law School. Hepatitis C: the state of Medicaid access. 2017 national summary report. Available at: https://stateofhepc.org/wp-content/uploads/2017/10/State-of-HepC_2017_FINAL.pdf. Accessed 23 October 2017.
20. Lynch TG, McCarthy ME. Hepatitis C virus funding and prioritization status update (February 24, 2016). Available at: http://www.hcvguidelines.org/pdf/choice-prioritization-update.pdf. Accessed 6 October 2017.
21. Edlin BR. Access to treatment for hepatitis C virus infection: time to put patients first. Lancet Infect Dis 2016; 16:e196–201.
22. Hirsch BR, Bahi S, Schulman KA. The impact of specialty pharmaceuticals as drivers of health care costs. Health Aff 2014; 33:1714–20.
23. Hennessy S, Bilker WB, Weber A, Strom BL. Descriptive analyses of the integrity of a US Medicaid claims database. Pharmacoepidemiol Drug Saf 2003; 12:103–11.
24. Blumenthal D, Davis K, Guterman S. Medicare at 50–moving forward. N Engl J Med 2015; 372:671–7.
25. Blumenthal D, Abram M, Nuzum R. The affordable care act at 5 years. N Engl J Med 2015; 372:2451–8.
26. Centers for Medicare & Medicaid Services. Medicaid drug rebate notice: Assuring Medicaid beneficiaries access to hepatitis C (HCV) drugs. Available at: https://www.medicaid.gov/medicaid/prescription-drugs/hcv/index.html. Accessed 20 October 2017.
27. Alexeeva J. Judge orders Washington Medicaid to provide lifesaving hepatitis C drugs for all. Available at: http://www.seattlepi.com/seattle-news/health/judge-orders-apple-health-to-cover-hepatitis-c-drugs-for-all/. Accessed 17 October 2017.
28. Rini J. State changes hep C medication guidelines, avoids lawsuit. Available at: http://www.delawareonline.com/story/news/health/2016/06/07/state-changes-hep-c-medication-guidelines-avoids-lawsuit/85554396/. Accessed 9 October 2017.
29. American Civil Liberties Union. ACLU files class action lawsuit against Colorado Medicaid over unlawful hepatitis C treatment restrictions. Available at: https://www.aclu.org/news/aclu-files-class-action-lawsuit-against-colorado-medicaid-over-unlawful-hepatitis-c-treatment. Accessed 18 October 2017.
30. Code of Federal Regulation. Title 42. Section 438.210. Coverage and authorization of services. Available at: https://www.ecfr.gov/cgi-bin/text-idx?rgn=div5&node=42:4.0.1.1.8. Accessed 2 November 2017.
31. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015; 162:407–19.
32. Rein DB, Wittenborn JS, Smith BD, et al. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 2015; 61:157–68.
33. Chahal HS, Marseille EA, Tice JA, et al. Comparative clinical effectiveness and value of novel interferon-free combination therapy for hepatitis C genotype 1: summary of California Technology Assessment Forum Report. JAMA Intern Med 2015; 175:1559–60.